SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021

Yi, Seonju; Choe, Young June; Kim, Jia; Kim, Yoo-Yeon; Kim, Ryu Kyung; Jang, Eun Jung; Lim, Do Sang; Byeon, Hye Ryeon; Lee, Sangwon; Park, Eonjoo; Kim, Seung-Jin; Park, Young-Joon

doi:10.3201/eid2803.212210

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021

3 2022
By Yi, Seonju ; Choe, Young June ; Kim, Jia ; ...
http://dx.doi.org/10.3201/eid2803.212210
Source: Emerg Infect Dis. 2022; 28(3):753-756

[PDF-821.35 KB]

English

Details Supporting Files You May Also Like

Details:

Alternative Title:

Emerg Infect Dis
Personal Author:

Yi, Seonju ; Choe, Young June ; Kim, Jia ; Kim, Yoo-Yeon ; Kim, Ryu Kyung ; ... More +

Yi, Seonju ; Choe, Young June ; Kim, Jia ; Kim, Yoo-Yeon ; Kim, Ryu Kyung ; Jang, Eun Jung ; Lim, Do Sang ; Byeon, Hye Ryeon ; Lee, Sangwon ; Park, Eonjoo ; Kim, Seung-Jin ; Park, Young-Joon Less -
Description:

We conducted a nationwide retrospective cohort study to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection among recipients of 4 different vaccines in South Korea. Age-adjusted breakthrough infection rate per month was highest for Janssen (42.6/100,000 population), followed by AstraZeneca (21.7/100,000 population), Pfizer-BioNTech (8.5/100,000 population), and Moderna (1.8/100,000 population).
Subjects:

[+]

Covid-19 Covid-19 Vaccines* Humans Retrospective Studies Sars-Cov-2
Source:

Emerg Infect Dis. 2022; 28(3):753-756
Pubmed ID:

35202529
Pubmed Central ID:

PMC8888240
Document Type:

Journal Article
Genre:

Letter
Place as Subject:

Republic of Korea
Volume:

28
Issue:

3
Collection(s):

Emerging Infectious Diseases
Main Document Checksum:

[+]

urn:sha256:7da5a6d5efab49e9cae6e2ba9224dd19e02d3ff62475f07b9f99c6d6447c18c2
Download URL:

https://stacks.cdc.gov/view/cdc/115229/cdc_115229_DS1.pdf
File Type:

	21-2210-F.gif	gif
	21-2210-F.jpg	jpeg
	21-2210-Techapp-s1.pdf	pdf
	21-2210.nxml	xml

More +